AlloMap gene expression profiling is used by over 90% of US transplant centers, and since approval has been used over 150,000 times in nearly 30,000 patients.
HeartCare provides a comprehensive assessment of graft rejection by combining AlloMap Heart gene expression profiling with AlloSure® Heart dd-cfDNA
Pipeline
CareDx is continuing to innovate with new products and post-market approval studies